Addressing Treatment Gaps in Gout

About this episode

James Mackay discusses the biology of gout and the potential of a next-generation urate inhibitor to improve treatment outcomes.

Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source of silent suffering for millions of people who are often blamed for their disease rather than offered effective care. Current therapies to lower urate levels suffer from limitations and safety challenges. Crystalys Therapeutics is in late-stage development of a next‑generation urate inhibitor that is already approved in Japan and China. Crystalys CEO James Mackay discusses the biology of gout, why standard therapies often fail to get uric acid to target levels, and how the company’s next‑generation URAT1 inhibitor may fill the treatment gap and change daily life for patients living with moderate to severe gout.

People in this episode

Guest: James Mackay

Topics covered

• gout
• arthritis
• urate inhibitors
• treatment gaps
• healthcare

Keywords

• gout
• urate levels
• arthritis
• treatment
• Crystalys Therapeutics
• healthcare
• inhibitor

Mentioned in this episode

Organizations: Crystalys Therapeutics, Levine Media Group

Books & works: Addressing Treatment Gaps in Gout

More episodes of The Bio Report

• Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug · June 10, 2026 · 28 min
• Rewriting the Rules of Antibody Drug Design · June 3, 2026 · 38 min
• Mapping Cellular Stress Biology to Tackle Undruggable Targets · May 27, 2026 · 30 min
• Turning Abandoned Drugs into Breakthroughs · May 20, 2026 · 31 min
• Targeting Cancer Survival Genes in Solid Tumors · May 13, 2026 · 46 min
• An Off-the-Shelf Cell Therapy to Calm Cytokine Storms · April 29, 2026 · 28 min